Stock Events

Helix Biopharma 

$0.1
3
-$0.04-27.43% Wednesday 13:30

Statistics

Day High
0.15
Day Low
0.15
52W High
0.18
52W Low
0.15
Volume
1,000
Avg. Volume
18
Mkt Cap
31.42M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

1NovConfirmed
Q3 2020
Q4 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-0.02
-0.01
-0.01
0
Expected EPS
N/A
Actual EPS
-0.0063

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HBPCF. It's not an investment recommendation.

About

Pharmaceuticals: Generic
Health Technology
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Show more...
CEO
Employees
9
Country
US
ISIN
US4229101096

Listings